Suggestions
Jarret Glasscock
Chief Executive Officer at Cofactor Genomics Inc.
Jarret Glasscock is the Chief Executive Officer of Cofactor Genomics Inc., a company specializing in RNA diagnostics. He co-founded Cofactor Genomics and has been instrumental in its growth and development since its inception. Under his leadership, the company has focused on bringing RNA-based discovery and diagnostics products to market, achieving significant annual growth.
Professional Background
-
Current Role: Glasscock has served as CEO of Cofactor Genomics since January 2016. He has been pivotal in steering the company's strategic direction and technological advancements in RNA diagnostics.
-
Previous Experience: Before his current role, he was the Founder and CEO of Cofactor Genomics, LLC, from 2010 to 2015, where he led the company in providing pharma sequencing services. His earlier positions include roles as a Research Faculty member at the Washington University Genome Sequencing Center and various leadership positions in computational biology and genomics.
Education
Glasscock holds a Bachelor of Science degree in Biology and Computer Science from the University of Arizona and completed his PhD in Genetics at Washington University School of Medicine in St. Louis, focusing on computational biology and molecular genetics.
Contributions and Interests
In addition to his role at Cofactor, he has served on the Industry Advisory Board for the Bioinformatics and Computational Biology Degree Program at Saint Louis University since 2014 and was a Senior Venture Partner at Pioneer Fund, supporting healthcare and biotech startups. His work emphasizes the importance of RNA in precision medicine and biomarker development, making significant contributions to the field through both leadership and research initiatives.1
Highlights
Proud to be invited to speak alongside many of my colleagues at this year’s RNA Leaders USA Congress. I'm speaking on the first day!
I will be covering progress on Cofactor’s mission to build RNA models that solve the current precision medicine gap holding back the promise of cancer immunotherapy.
Most importantly, I am excited to share recent clinical trial results in collaboration with dozens of US healthcare systems that show these RNA models are moving well beyond current clinical capabilities in predicting patient response to immunotherapy.
https://lnkd.in/ggaDxbq3 #rnaleaders #RNA #mRNA #RNAi
A big win announced today as we move into clinical use and bring precision medicine to immunotherapy and those patients with head and neck cancer. Humbled and grateful to the Cofactor team and the hundreds of people working across the nation at our 25 partnered healthcare systems to make this a reality. #cancer #immunotherapy #precisionmedicine #precisiononcology
